Tivic Health Systems, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Tivic Health Systems, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $780.0K | Mar 21, 2025 |
| FY2024 | Dec 31, 2023 | $1.18M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $1.84M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $1.26M | Mar 31, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.0K | Mar 21, 2025 |
| FY2024 | Dec 31, 2023 | $287.0K | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $299.0K | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($38.0K) | Mar 31, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.88M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($5.66M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($8.24M) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | ($10.10M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($8.49M) | Mar 31, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.90M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($4.48M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($8.25M) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | ($10.10M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($5.63M) | Mar 31, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.13M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $1.31M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $1.66M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $1.73M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $878.0K | Mar 31, 2023 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.77M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $3.16M | Mar 30, 2026 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.00M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($5.73M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($8.51M) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | ($8.92M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($5.61M) | Mar 31, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $118.0K | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $11.0K | Mar 25, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.61M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $2.81M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $5.16M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $5.88M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $15.04M | Mar 31, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.44M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $272.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $1.58M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $2.25M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $1.76M | Mar 31, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.80M | Mar 30, 2026 |
| FY2025 | Sep 30, 2025 | $3.41M | Mar 30, 2026 |
| FY2025 | Jun 30, 2025 | $3.31M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $2.54M | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $3.58M | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | $3.63M | Mar 21, 2025 |
| FY2023 | Dec 31, 2021 | $13.27M | Mar 25, 2024 |
| FY2022 | Dec 31, 2020 | ($1.18M) | Mar 31, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.46M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 30, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($52.60M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($43.54M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($37.89M) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | ($29.64M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($19.55M) | Mar 31, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.65M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $2.00M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $3.40M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $3.52M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $12.98M | Mar 31, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (7) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (19) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (176) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | (104) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (19) | Mar 21, 2025 |
| FY2024 | Dec 31, 2023 | (176) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | (104) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 31, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2.53M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 556,902 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 86,241 | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | 96,778 | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | 9.72M | Mar 31, 2023 |